TBPH
Theravance Biopharma Inc
17.00$
+0.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -11.1% | +113.0% | -31.0% | +26.9% | -27.0% | +14.7% | -20.1% | +62.1% | -37.1% | -7.3% | +37.1% | |
| – | -27.3% | +122.6% | -28.3% | +40.7% | -36.5% | +16.2% | -36.5% | +41.5% | -62.2% | +20.6% | +159.8% | |
| – | +26.3% | +205.8% | -74.2% | +324.8% | -84.6% | +40.3% | +10.4% | +231.5% | -86.7% | -4.4% | +344.0% | |
| – | -43.7% | +190.6% | -30.4% | +45.0% | -44.4% | +4.3% | -40.8% | +88.8% | -68.7% | -13.7% | +256.9% | |
| – | +1,645.1% | -75.6% | -21.7% | +50.1% | +373.8% | +37.8% | -17.3% | -70.9% | +4.1% | +291.7% | +39.6% | |
| – | -20.3% | +22.1% | +37.7% | -100.0% | +0.0% | +2,037,399,900.0% | -49.7% | -85.2% | -100.0% | -6,851,300,100.0% | – | |
| – | +2.2% | -14.3% | +20.1% | +29.7% | -4.0% | +29.9% | +224.9% | -77.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +18.9% | +406.6% | +12.9% | +87.5% | +3.4% | +22.2% | -7.7% | -76.8% | +2.1% | +5.7% | +5.7% | |
| – | +19.9% | -0.4% | +27.0% | +57.6% | +13.3% | +10.6% | -52.6% | -51.0% | -13.7% | +29.5% | +19.4% | |
| – | +0.0% | -0.1% | +0.5% | – | – | +65.8% | -40.3% | -61.3% | -41.9% | +173.1% | +2.2% | |
| – | +89.5% | -90.8% | +241.8% | +52.4% | -47.3% | +42.4% | -54.3% | -49.8% | -1.9% | +47.1% | +14.5% | |
| – | – | – | +0.5% | +103.1% | -2.0% | -49.0% | +164.1% | – | – | – | – | |
| – | -16.1% | +44.1% | -67.1% | -144.8% | – | – | – | – | -51.8% | -17.6% | +69.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +7.5% | +30.9% | +17.1% | +3.1% | +3.0% | +12.1% | +11.4% | +5.9% | -24.9% | -11.7% | +5.4% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.